Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.The company was founded in 2003 and is headquartered in San Diego, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 15, 2019 | Series B | $100M | 1 | — | — | Detail |
May 14, 2018 | Series A | $85M | 2 | Lilly Asia Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | — | Series B |
Joincap Investment | — | Series A |